News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Vivalis Grants Research License to Acambis (ACAM) to Evaluate E B66(R) Cell Line for Viral Vaccines Production


7/9/2008 8:38:59 AM

NANTES, FRANCE and CAMBRIDGE, MA--(Marketwire - July 08, 2008) - Vivalis (NYSE Euronext : VLS) announced today that it has granted ACAMBIS INC. (LSE : ACM) rights to the avian embryonic stem cell derived eb66® cell line to evaluate it as a production platform of viral vectors and vaccines.

Read at BioSpace.com

comments powered by Disqus
   
Vaccine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES